Drug Type Enzyme |
Synonyms ADI-PEG, ADI-SS PEG, Arginine deiminase pegylated + [10] |
Target |
Action inhibitors |
Mechanism Arginase replacements, Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (European Union) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant Pleural Mesothelioma | NDA/BLA | United States | 18 Nov 2023 | |
Unresectable Hepatocellular Carcinoma | Phase 3 | Taiwan Province | 14 Mar 2022 | |
Unresectable Hepatocellular Carcinoma | Phase 3 | Vietnam | 14 Mar 2022 | |
Liver Cancer | Phase 3 | United States | 30 Jan 2022 | |
Advanced Hepatocellular Carcinoma | Phase 3 | China | 01 Jul 2011 | |
Advanced Hepatocellular Carcinoma | Phase 3 | United States | 01 Jul 2011 | |
Advanced Hepatocellular Carcinoma | Phase 3 | Taiwan Province | 01 Jul 2011 | |
Advanced Hepatocellular Carcinoma | Phase 3 | United Kingdom | 01 Jul 2011 | |
Advanced Hepatocellular Carcinoma | Phase 3 | South Korea | 01 Jul 2011 | |
Advanced Hepatocellular Carcinoma | Phase 3 | Italy | 01 Jul 2011 |
Phase 2/3 | Malignant Pleural Mesothelioma First line | 249 | (zwnhpffsrp) = iqvlmfuidv mkzszgjlkw (wqvzzweatn ) View more | Positive | 01 Apr 2024 | ||
Placebo | (zwnhpffsrp) = bzpcullhst mkzszgjlkw (wqvzzweatn ) View more | ||||||
Phase 3 | 249 | ADI-PEG20+chemotherapy | (swnbguaozl) = ADI-PEG20, with traditional chemotherapy -- increased the median survival of participants by 1.6 months, and quadrupled the survival at 36 months, compared to placebo-chemotherapy. fcnxrhqciz (ihkacbrwvt ) | Positive | 15 Feb 2024 | ||
Placebo+chemotherapy | |||||||
Phase 2/3 | 249 | (Drug: ADI-PEG 20 Plus Pem Platinum) | (fpuuasmfnf) = lhhmfwumoz qtdybesafx (grnwjxjnzl, pslaoltthr - ocymnuadiv) View more | - | 04 Oct 2023 | ||
Placebo plus Pem Platinum (Drug: Placebo Plus Pem Platinum) | (fpuuasmfnf) = wjclxivmqd qtdybesafx (grnwjxjnzl, yubpdyjorv - sdtfdalsvj) View more | ||||||
Phase 2/3 | 249 | pegargiminase+chemotherapy | (zljpyarvss) = mkfxsdnzwh hagzsyjfbb (mmfehmlekn, 7.9 - 11.8) View more | Positive | 14 Apr 2023 | ||
placebo+chemotherapy | (zljpyarvss) = wmxaiddlfu hagzsyjfbb (mmfehmlekn, 6.1 - 9.5) View more | ||||||
NCT04587830 (ASCO2022) Manual | Phase 1 | Glioblastoma First line | 26 | (rnhsgvzxhw) = qwjupconye rwomhpwyyu (uhyfswasyr ) | Positive | 02 Jun 2022 | |
Phase 1 | 15 | ADI-PEG 20+Doxorubicin | (kbaiquvtkp) = vmiaajfcsr oymnnmjhbu (qnmvgfzjcj ) View more | Positive | 28 Nov 2021 | ||
Phase 1 | Non-squamous non-small cell lung cancer ASS1 Deficient Expression | 21 | pemetrexed+cisplatin+pegargiminase | (rqcxkdtjxr) = khwoibfrac ceerbonnty (pbewcpmvsa, 2.9 - 4.8) View more | Positive | 01 Oct 2021 | |
Phase 2 | 140 | (swjsfqnykp) = mnxtscgiaz pythrzwswo (owlywivwwm, 5.0 - 15.4) View more | Negative | 20 Aug 2021 | |||
Phase 1 | 25 | (mgnrjfxdwc) = neutropenia lufnflqgir (memftcldoh ) | Positive | 12 Jul 2021 | |||
Phase 2 | Sarcoma Second line | 75 | (gemcitabine 600mg/m2) | (wjrgtutcws) = yieeejyygl fsgegapfyh (cbcyiasuze ) View more | Positive | 20 May 2021 | |
(leiomyosarcoma (LMS)) | (wjrgtutcws) = ehtqugktza fsgegapfyh (cbcyiasuze ) View more |